
    
      A double-blind, randomized, placebo-controlled phase I/II study to evaluate the safety and
      tolerability of eltrombopag olamine, a thrombopoietin receptor agonist, administered for 6
      months as oral tablets once daily in adult subjects with advanced MDS, sAML/MDS, or de novo
      AML. Study medication may be increased up to 300 mg (150 mg maximum dose for East Asian
      subjects), based upon individual platelet counts and bone marrow blast counts.
    
  